GlassScriptPhysician profile
Richard K Olsen
NPI 1932157138
$6,272.65
in general payments reported to CMS, 2019-2025
41 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $266 · 2021: $542 · 2022: $1,414 · 2023: $1,482 · 2024: $1,026 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,601.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,429.69 | 2019-2025 | |
| Abbott Laboratories | $586.22 | 2020-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $559.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $550.49 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $482.63 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $336.14 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.60 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Astellas Pharma US INC | $285.42 | 2022-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $265.74 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $146.19 | 2021-2025 | |
| Amgen INC. | $135.43 | 2022-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $114.20 | 2021-2025 | Verquvo, Capvaxive, Steglatro |
| Sumitomo Pharma America, INC. | $84.31 | 2023-2024 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $70.86 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $68.54 | 2023-2025 | Ingrezza, Ongentys |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.